Superantigens are thought to make external contacts with major histocompatibility complex (MHC) class II molecules and with the VB portion of a T cell antigen receptor (TCR), thereby stimulating entire families of T cells. The precise mapping of superantigen binding sites on class II molecules may provide valuable information on how TCR and MHC molecules interact. Two bacterial superantigens, staphylococcal enterotoxins A and E (SEA/SEE) bind well to most HLA-DR alleles, but poorly to HLA-DRw53. The sequences responsible for this binding were localized to the putative oe helix of the DR 3 chain by measuring toxin binding to a panel of chimeric class II molecules expressed on transfected cells. Binding of SEA/SEE to the DRw14 (Dw9) molecule suggested that the conserved histidine 81 in the ~ chain of most DR molecules was important, whereas the tyrosine 81 in the DRw53/J chain was detrimental for high-affinity binding. To prove this, reciprocal point mutations were introduced in the DR1 and DRw53 chains. Mutation of histidine 81 in the DR1 3 chain to tyrosine reduced SEA/SEE binding, but did not prevent recognition of two DRl-restricted peptides by six of eight antigen-specific T cell lines. Conversely, introduction of histidine at position 81 in the DRw53 3 chain restored normal levels of SEA/SEE binding. These data suggest that a binding site of SEA and SEE lies on the outer face of the B chain oe helix, pointing away from the antigen-binding groove.
T
he class II molecules of the MHC include the HLA-DR, -DQ, and -DP antigens in humans, and the IA and IE antigens in the mouse. They are polymorphic cell surface heterodimers consisting of a noncovalently-associated "o35,000-dalton oe chain and a "o29,000-dalton/3 chain (1, 2) . Class II molecules function by binding small (9-12 amino acid) peptides derived from the processing of exogenous macromolecular antigens and subsequently presenting them to CD4 + T lymphoeytes. Little is known about the physical interaction of class II molecules with their principal ligands, the TCR variable regions and the T cell coreceptor CD4. Models have been proposed predicting the way that MHC molecules may interact with CD4 and TCR (3, 4) , but due to the low avidity of these interactions, no direct binding data have been reported.
Certain bacterial toxins are also ligands for class II. These include the Staphylococcus aureus enterotoxins (SEA, 1 SEB, 1Abbreviations used in this paper: Mls, minor lymphocyte system; SE, staphylococcal enterotoxin; TSST, toxic shock syndrome toxin.
A preliminary account of this work was presented at the Federation of American Societies for Experimental Biology, Atlanta, GA, April 21-25, 1991. SECI,2,3, SED, and SEE) and the toxic shock syndrome toxin (TSST-1). The staphylococcal toxins are potent polyclonal activators of T cells (5, 6) . There is no requirement for processing of the toxins similar to typical antigens. Proteolysis of the toxins abrogates their activity (7) . The activation of T cells results in proliferation, cytolytic activity, and secretion of IL-2 and IFN-3,. T cell populations activated by the staphylococcal toxins are polyclonal, yet each superantigen appears to preferentially stimulate T cells bearing TCR representing one (or a few) particular V3 family (8, 9) . Direct binding of many of the toxins to class II has been demonstrated: SEA and SEB to HLA-DR (7); SEA to HLA-DR, -DQ, and -DP (10); and TSST-1 to HLA-DR and -DQ, but not to HLA-DP (11) . The Kd's for the interaction of the various toxins with class II molecules determined were in the range of 10-6 to 10 -s M.
The term superantigen has been used to describe substances with the ability to activate large numbers of T cells in a class II-dependent but unrestricted fashion (8) . The staphylococcal toxins are the best studied super'antigens, but there is a growing number of microbial products that fit this category. These include the Mycoplasma arthriditis mitogen (12) and the streptococcal M protein (13) . Other superantigens have been partially characterized from group A streptococcus and Gramnegative bacteria. The Mls (minor lymphocyte system) in mice has aspects of a superantigen-mediated phenomenon (6) . Particular Mls determinants are associated with specific endogenous murine retroviruses (14) (15) (16) . In one case, the Mls response was duplicated by transfection of lymphocytes with DNA derived from an open reading frame in the 3' retroviral LTK (17) . Other retroviral proteins have been suggested to act as superantigens (18) .
The molecular mechanism by which the toxins interact with class II is poorly understood. The toxins appear to bind outside the antigen-binding groove of class II. Preincubation of HLA-DK-expressing cells with a saturating amount of TSST-1 neither prevented nor diminished the binding of a known antigenic peptide (19) . Furthermore, an alaninescanning mutagenesis of the oe-helical portion of the IA k ol chain failed to identify a residue that was essential for SEB, SEC1, or exfoliative toxin action, whereas many mutants affected the recognition of specific antigenic peptides by T cells (20) . The conclusion that the toxins make external contacts with class II molecules is consistent with the observation that residues of the Vfl region of the TCK that are important for toxin action are postulated to lie on an exposed face of the receptor (21) . The precise mapping of superantigen binding sites on class II molecules would provide valuable information about how MHC and TCK interact.
Several clues to the nature of the toxin binding site(s) have been derived from the hierarchy of interaction that exists for many of the isotypes and alleles of class II. The oll domain of HLA-DK1 was shown to be essential for the high-affinity binding of TSST by producing a series of homologue scanning mutants with sequences derived from the DR or the DP molecules (19) . The importance of the DR o~ chain in TSST binding was confirmed by testing mouse/human hybrid class II molecules (22) . The mouse IE molecule, although homologous to DR, does not bind TSST. Cells expressing class II consisting of the DR o~ chain in combination with the IE 3 chain bound TSST, and cells expressing an IE oe/DR,8 heterodimer did not. Several toxin binding sites may exist on class II molecules. TSST and SEB bind independent of each other to HLA-DK1 or HLA-DQwl (23) . In addition, SEA is an effective competitor of SEB binding to HLA-DR, and SEB did not inhibit the binding of SEA, even at a 1,000-fold excess (7) . SEA can also inhibit TSST binding, and, again, the converse is not true (D. Karp, unpublished results) . This suggests the possibility of several, possibly overlapping, binding sites for the staphylococcal toxins on class II.
The HLA-DRw53 molecule was found to be ineffective in the binding of SEA and SEE when compared with HLA-DR1 (24) . This molecule is composed of the nonpolymorphic DR o~ chain and the DRw53 ~ chain (DRB4*0101 allele). This suggested a binding site for SEA and SEE in the B chain, a conclusion supported by peptide inhibition experiments (25) . The present investigation uses molecular techniques to identify residues critical for binding of SEA and SEE. Mutant human class II molecules containing sequences from DR1 and DRw53 localize the binding of intact toxins to the putative ol-helical region of the 81 domain. Site-directed mutagenesis has identified position 81 of the B chain as a critical residue in the interaction with these two toxins.
Materials and Methods
L Cells Expressing HLA-DR Mutants. Expressible cDNA for the/3 chain of DR1 was cloned into the vector KSV.3 as described (26) . This construct has unique Sad and HindlII restriction endonuclease sites in the DR leader sequence and 3' untranslated region, respectively. These sites are conserved in cDNA for many DIL8 alleles including DKw53 and DKw14(Dw9). The plasmid, KSV.3 DK1/3, was digested with Sad and HindIII, and the DK1 /3 chain coding sequence rephced by cDNA from DKw53 (provided by Dr. Kobert Karr, Monsanto Corp., St. Louis, MO) and DKw14 /3 chains (provided by Dr. Jack Gorski, Blood Research Institute, Milwaukee, WI), digested with the same enzymes.
The cDNA for DR1 and DRw53/3 chains were also cloned into the vector pBluescript SK (Stratagene Inc., La Jolla, CA) to create pSKDR1/3 and pSKDKw53/3, respectively. A unique ScaI site occurs at codon 59 of the/3 chain sequence. Digestion of pSKDK1/3 and pSKDKw53/3 with ScaI and ClaI produced three fragments: a ClaI-ScaI fragment containing NH2-termina] cDNA sequences, a ScaI-ScaI fragment including COOH-terminal cDNA sequences and a portion of the vector, and a ScaI-ClaI fragment having the remainder of the vector. These fragments were separated by gel electrophoresis and appropriate fragments were isolated and religated. This created two chimeric cDNA molecules. DR. 153.59 had codons 1-59 derived from DR1 and the remainder from DRw53, DR 531.59 had codons 1-59 from DR`w53, and the remainder from DR1.
To create the pair of mutants having/31 domains (codons 1-94) derived from either DR`I or DR`w53, and/32 domains (codons 95-237) derived from the other allele, the technique of synthesis by overlap extension was used (27) . Oligonucleotides were synthesized corresponding to conserved regions of the DR`/3 chain cDNA sequence in the leader region (codons 1-6, sense direction), the cytoplasmic tail (codons 224-230, antisense direction), and the COOH-terminal portion of the/31 domain (codons 88-94, both directions). These oligonucleotides were used to amplify 81 and /32 domain sequences from DR`I and DR`w53/3 chain cDNA using PCR`. Amplified products were isolated by agarose gel electrophoresis, and purified with GeneClean (Biol01, Inc., Vista, CA). DNA corresponding to the/31 domain of DR`l was combined with DNA for the/32 domain of DRw53, and oligonucleotide primers from the leader and cytoplasmic regions. After a second amplification by PCR, the full-length products were isolated by gel electrophoresis, purified, and digested with Sad and StuI. These fragments were ligated to fragments of RSV.3 DR1/3 and ILSV.3 DR`w53/3 digested with these same enzymes. This created DR` 153.94 (having the/31 domain of DR1 and/32 domain of DKw53) and DR` 531.94 (having the/31 domain of DKw53 and/32 domain of DR`l).
Point mutations in the/3 chain cDNA were made in a similar manner. Oligonucleotide primers corresponding to codons 78-84 (both directions) of the DR`I and DR`w53 B chains were synthesized such that codon 81 of the DR`I sequence would be a tyrosine and codon 81 of the DR`w53 sequence would be histidine. These primers were used with the primers from the leader and cytoplasmic sequences described above to create full-length cDNA having the single amino acid change. Fragments of these cDNA were used to replace sequences from R`SV.3 DR`l/3 or R`SV.DR`w53/3, as appropriate. The authenticity of the point mutations, as well as the chimeric cDNA sequences, was verified by determining the sequence of the the entire/3 chain coding region of each clone before use in transfection experiments.
The plasmid, R`SV.5(neo) DR`or (28) has an expressible cDNA for the nonpolymorphic DR` c~ chain under the control of the RSV LTR`, as well as the bacterial neomycin resistance gene under the control of the SV40 early region promoter. This plasmid was cotransfected with an expressible wild-type or mutant fl chain eDNA into L cells as described (28) . Transfected cells were selected and maintained in DME plus 10% FCS containing G418 (0.5 mg/ml, active drug, Gibco-Bethesda Research Laboratories, Gaithersburg, MD). Surviving cells from each transfection were pooled and stained with the anti-DR mAb, L243. A FACStar Plus | flow cytometer (Becton Dickinson and Co., Mountain View, CA) equipped with an Automatic Cell Deposition Unit was used to clone transfected cells on the basis of surface expression of DR molecules.
Toxin Binding Assay. SEA, SEK SEE, and TSST were were all purchased lyophilized from Toxin Technologies (Madison, WI). They were dissolved in sterile water at a concentration of 1 mg/ml and diluted to 10 #g/ml in PBS containing 1% BSA and 0.1% gelatin just before use. 5 x 10 s L cells were incubated at 4~ with the various toxins for 2 h. The cells were washed, then incubated with toxin-specific polyclonal rabbit antiserum (Toxin Technologies), diluted 1:100 in PBS/BSA/gelatin, and incubated on ice for I h. Cells were washed again and incubated for 30 min on ice with FITC-labeled goat anti-rabbit IgG. Bound toxin, was determined by microcytofluorimetry. Controls for each cell type were incubated with antitoxin and fluoresceinated antibody without prior toxin binding. Each cell type was simultaneously analyzed for L243 binding. Data for toxin binding are corrected for different levels of class II expressed by different transfectants as follows: (PCFto~n/ PCR~ontrol) -1]/(PCFL243/PCFG^Mm). Where PCF,o~ is the peak fluorescence value in the presence of toxin, PCFcon,rol is the value in the absence of toxin, PCFL243 is the peak fluorescence of the anti-DR reagent, PCFc~a~G is the fluorescence of the second antibody alone. The toxin/control ratio is reduced by 1 to reveal the fractional increase in fluorescence due to toxin binding.
T Cell Lines.
Fresh PBL were obtained from a normal HLA-DR1 volunteer. 13 x 106 cells were seeded in 10 ml of IMDM supplemented with 2 mM t-glutamine, 10% human serum, and 5/zg/ml of either influenza matrix peptide M1 (18) (19) (20) (21) (22) (23) (24) (25) (26) (27) (28) (29) or hemagglutinin peptide H3(307-318). After 10 d, 103 live cells were transferred into wells of a 24-well plate containing 2 ml of IMDM supplemented with glutamine, 10% human serum, and 106 feeder cells. Feeder cells were prepared by incubating autologous PBL in IMDM supplemented with glutamine and 10/~g/ml of either peptide for 3 h, irradiated (2,000 tad), and washed. After 6 d, 106 live cells were restimulated in a volume of 5 ml with 3-4 x 10 ~ irradiated feeder cells prepared as above. After five additional days, responder T cells were assayed for their ability to lyse target B cells incubated with peptide. Both the M1-and H3-stimulated population of T cells displayed peptide-specific target cell lysis. 2 d later, T cells were seeded at 10 cells/well in three round-bottomed 96-well plates. Each well contained 0.2 ml IMDM supplemented with glutamine, human serum, and 25 U/ml rib2 (Cdlular Products, Buffalo, NY), and 103 irradiated and peptide-pulsed autologous feeder cells. The first addition of exogenous Ib2 occurred at this cloning step. After 12 d, growing T cells were tested for their ability to kill target cells in a peptide-specific manner. Lines that displayed specificity were expanded by repeated stimulations at 5-6-d intervals with irradiated peptide-pulsed feeder cells, and addition of 5 U/ml rlL-2 1 d after restimulation. Based on their cloning efficiency, these lines are either clonal or oligoclonal.
Cytotoxicity Assays. Cytolytic activity was measured by standard chromium release assays. The HLA-hemizygous B cell line, 45.1 (29) , was used as a human DRl-positive target. About 0.5-1 x 10 ~ cells were incubated with 10/~g/ml of either matrix or hemagglutinin peptide in 0.5 ml of RPMI 1640 supplemented with ghtamine, 40/~g/ml gentamycin, and 5% bovine serum (Hyclone Laboratories Inc., Logan, UT). After 1 h, 50 ~Ci Na[SlCr]O~ was added, and the cells incubated another 3 • h. After two washes, 5 • 103 live target cells were added to various numbers of effector cells in V-bottomed 96-well plates. For staphylococcal toxinmediated cytotoxicity, 45.1 cells were incubated with either 0.1/zg/ ml SEA or 1/~g/ml SEE, as described above for peptide. When trypsinized L cells were used as target cells, they were incubated with 100 #g/ml of antigenic peptide and labeled as described above. 2.5 x 103 L cells were added to V-bottomed wells, and incubated 6 h with effector cells. E/T ratios of 10:1, 2.5:1, and 0.625:1 were used for B cell targets, and 20:1, 5:1, and 1.25:1 for L cells. Supernatants were harvested and counted. Percent specific lysis was calculated as 100 x [(experimental -spontaneous release)/(maximum -spontaneous release)]. Each point represents mean determinations from triplicate wells. Maximum and spontaneous release were determined by incubating targets in 1% Triton X-100 or medium, respectively.
T CellProliferation Assays. Purified T cells were prepared from peripheral blood of normal volunteers as previously described (30) . After rosetting with SRBC and treatment with t-leucine methyl ester, the cells were passed through nylon wool. Non-T cells were depleted by panning with mAb L243 (anti-HLA-DR), 63D3 (anti-CD14), and B73.1 (anti-CD16). L cell transfectants were treated with mitomycin C (Sigma Chemical Co., St. Louis, MO), 100 /~g/ml, at 37 ~ for 1 h and washed extensively. T cells (6 x 104) and L cells (2 x 104) were co-cultured in round-bottomed 96-well plates with various dilutions of SEA or SEE in RPMI 1640 containing 10% heat-inactivated FCS. After 50 h at 37~ the cells were pulsed with 1/zCi of [3H]thymidine (6.7 Ci/mmol), and cultured for an additional 16 h. Cells were harvested on glass fiber filters, and incorporated radioactivity was quantitated by liquid scintillation counting. (DRB1 "0101) or DKw53 (DRB4*0101) alleles, or chimeric chains having sequences from both DR1 and DRw53. These cells were tested for their ability to bind the staphylococcal enterotoxins, SEA, SEB, SEE, and TSST (Fig. 1 A) . As shown previously (24) , there was a marked difference between DR1 and DKw53 in the binding of SEA and SEE. For these two toxins, the level of binding to DKw53 (corrected for expression of class II) was 1-5% of that seen with DR1. In contrast, there was no significant difference in the binding of either SEB or TSST to DR1 or DKw53. The lower level of binding of these two toxins is consistent with their greater reported dissociation constants (31) .
Results

Binding of SEA and SEE to DR1 Is
Since the DR o~ chain is common to both DR1 and DRw53, the sequences responsible for the high-affinity interaction with SEA and SEE must lie in the B chain. To isolate the region of the B chain containing these sequences, a series of homologue scanning mutants were constructed. The first pair of these mutants combined the membrane distal fll domain of one allele (amino acids 1-94) with the B2 domain, transmembrane, and intracytoplasmic portions (amino acids 95-237) of the other. L cells expressing class II molecules comprised of these mutant ~ chains in association with the DR, cz chain were tested for toxin binding (Fig. 1 B) . Only the chimera DR 153.94, which expresses the/31 domain of DR1, was able to bind SEA and SEE. The reason for the increased binding of SEE to this mutant relative to the wild-type is unknown. The mutant DR, 531.94, expressing the 31 domain of DRw53, did not bind these two toxins, although it did bind SEB and TSST. The next pair of mutants had the first 59 amino acids derived from one allele and the remainder of the molecule derived from the other. Residues 1-59 are predicted to form the/3 sheet "floor" of the antigen-binding groove (32) . Thus, the mutant DR 153.59 had DRl-derived residues in the/5 sheet region, and DRw53-derived residues in the putative c~-helical portion of the antigen-binding domain, as well as in the/32 domain. The mutant, DR 531.59, had the/3 sheet from DRw53 and DR1 residues in the remainder of the molecule. This latter molecule was able to bind SEA and SEE, whereas DR 153.59 was not (Fig. 1 C) . This suggests that the residues responsible for the high-affinity binding of these two toxins lie in the region of residues 59-94. This was tested directly with a final pair ofhomologue mutants created from the first two. DR 1.53.1 had DRl-derived residues in the /3 sheet and/32 domains, and DRw53-derived residues in the or-helical portion of the/3 chain. DR 53.1.53 had the cx-helical portion (amino acids 59-94) derived from DR1, and the remainder of the/3 chain was derived from DRw53. As expected, only DR 53.1.53 bound SEA and SEE (Fig. 1 D) .
In each pair of homologous mutants, high-affinity binding of SEA/SEE was determined by sequences in the oe helix of the DR1 ~ chain, although other/3 chain sequences appeared to affect the quantitative level of this binding. Either there is participation of sequences outside the ot helix in direct SEA/SEE contact, or an influence on the conformation of the ot helix by amino acid residues that are distant in the/3 chain primary sequence but nearby in the tertiary structure.
Residue 81 Is Critical for SEA and SEE Binding. A com-
parison of the DR1 and DRw53/3 chain amino acid sequences from residues 59-96 is shown in Fig. 2 . There are five differences between these two alleles in this region. Positions 70, 74, 86, and 96 are all highly variable among the known/3 chain sequences and are presumably responsible for differences in antigen presentation among DR alleles. Previous reports have documented SEA binding by DR alleles differing from DR1 at one or more of these positions (10, 24) . In contrast, the occurrence of tyrosine at position 81 in the DRw53 /3 chain is unique to this allele. All other DR 3 chains, as well as the/3 chains of HLA-DQ, HLA-DP, I-E, and I-A (except A~ [33] ), have histidine at this position. The DRw14 (Dwg)/3 chain (DRBI*1401) is thought to be the result of a gene conversion event between the DRB1 and DRB4 loci (34) . The region coding for the/3 sheet portion of the/31 domain has nucleotide sequence similarity to several DRB1 alleles including DRw11, w12, w13, w17, and w18. However, the sequence in the oe helix appears to be derived from the DRw53 allele except that there is a histidine at position 81. The 32 domain of this allele appears to be derived from and DRw14 (Dw9). The protein sequence (single-letter amino acid code) from residue 59-96 is shown. Boxed residues are the allelic differences between DR1 and DRw53 in this region.
DR~ as well. An L cell transfectant expressing the DRw14 (Dw9) class II molecule was made and found to bind SEA and SEE (Fig. 3) . Thus histidine 81 was the most likely residue controlling SEA and SEE binding.
To test the role that residue 81 may play in the binding of SEA and SEE to HLA-DP,, a pair of point mutant/~ chains were synthesized. The first was a DP,1 B chain with tyrosine at position 81; the second was a DRw53 B chain with histidine at position 81. L cells expressing these mutant DR B chains in association with the wild-type DR o~ chain were tested for toxin binding (Fig. 3) . The mutant, DR1-81HY lost most, but not all, of the SEA and SEE binding seen with the wild-type DR1 molecule. More significantly, the mutant DRw53-81YH bound both toxins at levels comparable with other DR alleles. Therefore, the introduction of histidine at position 81 of the DR B chain restored SEA and SEE binding to a DR B chain which otherwise would be unable to bind these toxins.
Superantigen-induced T Cell Proliferation. The ability of point-mutated DR molecules to stimulate T cells in the presence of SEA or SEE was tested (Fig. 4) . As shown previously (24), DILw53 was much less e~cient than DR1 in the SEAinduced stimulation of purified T cells. Both the mutant DRw53 with histidine at position 81, and the mutant DR1 with tyrosine at position 81, were intermediate in the ability to stimulate T cells in the presence of SEA. The similarity in the ability of these two mutants to cause T cell proliferation is unlike their wide disparity in the ability to bind toxins at saturation (Fig. 3) . This is similar to previous data showing that HLA-DP can cause marked T cell proliferation in the presence of TSST although direct binding cannot be demonstrated (11) . T cell proliferation is therefore a more sensitive assay for the low level of toxin-class II interaction that results from the residual binding seen with DR1-81HY. It is not clear why there is submaximal T cell stimulation by the mutant DRw53-81YH, despite a high relative toxin binding (Fig. 3) . It is known that aUelic differences in class II that do not affect toxin binding result in variation in T cell stimulation by superantigens (24) . It is possible that structural features distinct from those responsible for SEA/SEE binding determine the ability of this allele to interact with T cell receptors when bound to these toxins. in DR1 abrogated the ability to bind SEA and SEE, not by selective disruption of the toxin binding site, but by causing more extensive changes in the conformation of the class II molecule. The L ceils expressing the class II point mutants DRI-18HY and DRw53-81YH were compared with cells expressing wild-type DILl or DRw53 for their ability to bind the mAbs SG465, L243, and SG250. The first two antibodies react with determinants that require both the ot and ~ chains of human class II (35) or HLA-DR, respectively. SG520 is specific for a monomorphic determinant on the/~ chain (36) .
There was no difference in the relative levels of staining among these three antibodies for any of the cell lines tested (data not shown), suggesting that the conformation of the mutants was not grossly altered. One of the most critical ways to evaluate the functional conformation of an MHC molecule is to test its ability to present peptide antigen. This requires that the ability to bind the particular peptide be preserved and that the peptide-MHC combination result in a recognizable TCR ligand. A panel of DKi-restricted human T cell lines specific for peptides de- Despite the fact that these transfectants expressed one-third to one-half the level of DR molecules present on the DR1-transfected L cells (not shown), most T cells were able to recognize peptide presented by the DR1-81HY molecule ( Fig.  5 and Table 1 ). Six of the eight T cell lines (three each of the anti-M1 and anti-H3) were able to lyse the transfectant expressing DR1-81HY after incubation with the relevant peptide. Thus, the failure of this class II molecule to bind SEA and SEE is not due to a significant conformational change in the/31 domain. However, the finding that two of the lines did not respond to DR1-81HY when pulsed with peptide suggests that the particular amino acid at residue 81 can dictate recognition by some T cell receptors. The binding of SEA and SEE to the region of the 3 chain surrounding position 81 of DR1 may prevent an interaction with those T cell receptors that are sensitive to changes in this portion of the class II molecule. To study this, the M1-and H3-specific T cell lines were tested for their ability to become activated by SEA, and SEE bound to DR1. The 45.1 B cells were incubated with the toxins, labeled with chromium-51, washed, and then used as target cells for the T cell lines. Four of the six lines evaluated responded by lysing the target cells in the absence of antigenic peptide (e.g., Fig. 5 , a and c). This included the two lines that required histidine at position 81 for recognition of peptide in the context of DR1. One of the lines, D1.10, was not stimulated at all by the toxins (Fig. 5 b) . This clone was able to recognize the H3 peptide regardless of the presence of histidine at position 81. The final T cell clone, B3.10, was stimulated by SEE but not SEA. Thus, while the interactions of certain TCK and SEA/SEE with class II molecules can be sensitive to changes in the same region of the DR ~ chain, these interactions are functionally distinct.
Discussion
Superantigens such as the SEs are potentially useful reagents for the study of MHC/TCR interactions. A first step in understanding how superantigens trigger T cells, and whether the topology of MHC/TCR is maintained when T cells respond to superantigens, is to define how these molecules bind to class II MHC molecules. The experiments reported here document the identification of a specific amino acid residue critical for the binding of native SEA and SEE to HLA-DR. The ability of class II molecules to bind these two toxins and subsequently stimulate T cells was dependent on the presence of histidine at position 81 of the ~ chain. This residue is part of a conserved sequence, C-R-H-N-Y, in the putative ol-helical portion of the 31 domain. It is found in all reported class II B chain sequences of humans and mice except the HLA-DRw53 and I-A u alleles. The single replacement of the tyrosine at position 81 of the DRw53 ~ chain by histidine was sufficient to restore normal binding of SEA and SEE, whereas most of the binding to DR1 was lost by the replacement of histidine by tyrosine.
The ability of the natural and mutated dass II molecules to stimulate T cells in the presence of SEA and SEE was similar qualitatively to the binding data. However, the mutant DR.w53-81YH was still less potent than DR.1. Conversely, DR1-81HY was still more potent than DRw53. These results are consistent with the possibility that polymorphic MHC residues contacting the TCR contribute to the T cell response in conjunction with the V3/superantigen contacts. Clonal T cells respond differently to the same toxin bound to different alleles of HLA-DR (24) . This would be in agreement with the view that superantigens strengthen rather than disrupt the class II/TCR interaction (6) .
The full extent of the binding site of SEA and SEE cannot be predicted from the data presented here. However, these experiments argue strongly that necessary contact residues are in the conserved sequence at positions 79-83 of the 3 chain. First, although the single amino acid substitutions described here may cause local changes in secondary structure, it would be unusual for them to cause global conformational changes affecting a distant binding site. Second, there was no difference in the reactivity of the two point mutants with a panel of mAbs to either monomorphic determinants located on the 3 chain alone or combinatorial determinants requiring both the ol and the 3 chains. Lastly, a majority of T cell lines specific for peptides derived from influenza and restricted by DR1 were capable of responding to these peptides presented by the mutant DR1-81HY. The interaction of T cell receptor with class II and peptide is complex, involving five separate polypeptide chains. It is therefore improbable that the mutation that caused a loss of SEA and SEE binding activity would also cause significant conformational changes in the rest of the class II molecule, particularly in the antigen-binding groove.
It is not surprising that SEA and SEE have similar class II binding characteristics. They are 82% similar in amino acid sequence and cross-react serologically (37, 38) . There are significant differences in their secondary and tertiary structures predicted by circular dichroism and fluorescence quenching (39) . The NH2-terminal portion of SEA (residues 1-45) has been suggested to be responsible for binding to class II molecules (25) . This region has extensive primary sequence similarity to SEE. In addition, both proteins are predicted to contain similar o~ helix and 3 sheet structures in this region. Other regions of these two toxins have much less similarity in the arrangement of putative helix, sheet, and fl turn structures. The functional consequence of this is the ability of certain T cell receptors to distinguish between SEA and SEE (Table 1 , clone B3.10).
The staphylococcal toxins SEB and TSST bind to distinct sites on HLA-DR (23) . SEA will compete with both of these toxins for binding to L cells transfected with DR1 (D. Karp, unpublished observations), suggesting that all three toxins bind to the same general region of class II, although with distinct contact points. The identification of histidine 81 as a critical element for SEA and SEE binding forms the starting point for further investigations into the nature of other toxin binding sites, with the aim of understanding how superantigens as MHC/TCR coligands (40) achieve their potent effects.
The current model of the three-dimensional structure of class II places residues 79-83 of the fl chain on a turn of oe helix with residue 81 facing away from the antigen-binding groove ( Fig. 6) (32) . This is appropriate if this sequence is involved in binding staphylococcal toxins. This portion of the helix also overlies the NH2-terminal end of the c~ chain, allowing a possible role for both chains in the toxin-class II interaction. There are strong theoretical and experimental reasons to model class II based on the class I crystal structure. However, it is not known how primary sequence differences between class I and class II will ultimately be reflected in the class II secondary or tertiary structure. For example, the region of the oe helix discussed above is predicted to be fl turn by both Gamier et al. (41) and Chou-Fasman algorithms (42) . The probability of a fl turn is much larger in the class II fl chain sequence than in the class I c,2 sequence. Obviously, there are other constraints on the structure in this region (including the disulfide bond between the oL helix and the fl strand beneath). A fl turn-like structure in this area would be an attractive feature for a protein-protein interaction such as toxin binding. The residues at positions 79-83 of the class II fl chain comprise the five amino acids with the highest degree of conservation across isotypic, allelic, and species boundaries. A potential physiologic role of this structural feature in the interaction with other ligands is not known.
